Todd Blanche, President Donald Trump’s pick to become the official U.S. Attorney General, faces critical obstacles ahead of his Senate Judiciary Committee hearings, where his nomination must secure committee approval before moving to the full Senate. Blanche has been serving in an acting capacity since Trump replaced the former department head.
Key issues complicate Blanche’s path, including controversies over how the Justice Department managed sensitive Jeffrey Epstein investigation files under his leadership. Advocacy groups representing Epstein survivors have criticized the DOJ for exposing the personal information of victims while heavily redacting names of alleged abusers and prominent individuals linked to Epstein. This blunder prompted calls from survivor organizations urging senators to reject Blanche’s confirmation. The Senate Judiciary Democrats have invited an Epstein survivor to testify during the upcoming hearings, signaling that this issue will receive significant scrutiny.
In addition to the Epstein case, Blanche faces significant opposition regarding the DOJ’s handling of state legal challenges to the distribution of mifepristone, a medication used for abortion, permitted by federal policy. Pro-life groups have demanded a tougher DOJ stance on these lawsuits, further intensifying the political debate around Blanche’s nomination.
Blanche’s nomination is also shadowed by bipartisan skepticism over the Trump administration’s proposed $1.8 billion “anti-weaponization fund.” The initiative, aimed at countering weapon misuse, has faced criticism from senators across party lines, complicating support for Blanche’s confirmation. These intertwined issues set the stage for a contentious Judiciary Committee hearing, where Blanche’s record and decisions as acting Attorney General will be examined in detail.